Address
100 Cambridgepark Drive
Cambridge, MA 02140
United States of America (the)
Phone
617 655 6580
Website
Sector
Healthcare
Industry
Biotechnology
Employees
159
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Jean-Paul Kress | Chairman, President & CEO | 1.01M | 1965 |
| Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | 603,814 | 1965 |
| Jeremy Sokolove | Chief Medical Officer | 695,160 | 1974 |
| Robert Ang MBBS | Strategic Advisor | 2M | 1975 |
| Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | 0 | 1971 |
| Carol Lincoln | Head of Human Resources | 0 | N/A |
| Navid Z. Khan | Chief Medical Affairs Officer | 0 | N/A |
| Adi Osovsky | General Counsel | 0 | N/A |
| Dallan Murray | Chief Commercial Officer | 0 | 1970 |
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.